Martin Welschof, PhD, Managing Director of Affitech A/S

Dr. Welschof is Managing Director of Affitech A/S. He served Affitech AS as its CEO for 5 years and later as COO. He co-founded Affitech AS while he was doing his post-doctoral training at the German Cancer Research Centre (DKFZ), Heidelberg, Germany.

After finishing his work at DKFZ where he established several important aspects of human antibody discovery systems, Martin Welschof joined Axaron Bioscience AG, Heidelberg, Germany in 1999. As the Director of its technology division, Martin Welschof oversaw the development of a large portfolio of cutting-edge technologies in the field of transcription analysis and functional genomics. Martin Welschof also worked at Axaron's parent company, LYNX Therapeutics Inc., Hayward, California, where he was instrumental in the development of LYNX's parallel cloning and sequencing technologies MegaClone, MegaSort and MPSS.